Pharmacokinetics of Estradiol Valerate 2mg + Dienogest 2mg (Climodien® 2/2) after Single and Repeated Oral Administration in Healthy Postmenopausal Women
- 82 Downloads
Objective: To evaluate the pharmacokinetics and tolerability of estradiol valerate 2.0mg plus dienogest 2.0mg (Climodien® 2/2).
Design and Setting: This was an open single-and multiple-dose study.
Study Participants: 16 healthy postmenopausal women.
Interventions: Pharmacokinetic parameters were determined in plasma after single and multiple daily intake of Climodien® 2/2 for 12 weeks. Accumulation during multiple administration was calculated from the area under the plasma concentration-time curve (AUC). Changes in plasma levels of other hormones and sex hormone-binding globulin (SHBG) were also measured.
Results: The observed accumulation of estradiol (accumulation ratio R1 = 3.3) and free estrone (R1 = 2.4) was higher than that predicted from single-dose data (Rtheor = 1.7 and 2.0 for estradiol and free estrone, respectively). This was thought to be due to high interindividual variability in estrogen parameters, or the degree of extrapolation required when calculating the half-life (t1/2). The observed accumulation of total estrone after multiple-drug administration was as predicted from single-dose results (R1 and Rtheor = 1.5). The pharmacokinetics of dienogest were not time dependent, the observed accumulation (AUC0–24h 627 vs 483 μg/L · h) was as predicted from single-dose results (R1 and Rtheor = 1.3). Reduced total plasma testosterone levels confirmed the antiandrogenic effect of dienogest.
The main adverse events with Climodien® 2/2 (breast tension in five participants and irregular vaginal bleeding in four) reflected its hormonal content, and laboratory screening tests revealed no tolerability concerns.
Conclusions: Estradiol may accumulate in plasma during multiple-drug administration with Climodien® 2/2 more than predicted from single-dose results. However, dienogest kinetics after multiple-drug administration were as predicted from single-dose results. Climodien® 2/2 demonstrated antiandrogenic effects and was well tolerated.
KeywordsEstradiol Estrone Dienogest Estradiol Valerate Bioequivalence Range
This study was sponsored by Jenapharm GmbH & Co. KG, Jena, Germany, a subsidiary of Schering AG, Berlin, Germany.
- 1.Stanczyk F. Introduction: structure-function relationships, metabolism, pharmacokinetics and potency of progestins. Drugs Today 1996; 32Suppl. H: 1–14Google Scholar
- 2.Gräser T, Oettel M. Organ targeting with the oral progestin dienogest. Drugs Today 1996; 32Suppl. H: 43–55Google Scholar
- 3.Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group 1: dienogest from a pharmacokinetic point of view. Drugs Today 1995; 31(7): 499–516Google Scholar
- 6.FDA HRT Working Group. Guidance for clinical evaluation of combined estrogen/progestin-containing drug products used for hormone replacement therapy of postmenopausal women. Menopause 1995; 2: 131–6Google Scholar
- 8.Luciano AA, Turksoy RN, Carleo J, et al. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen progestin replacement therapy. Obstet Gynecol 1988; 71:3–43Google Scholar
- 11.Anderson ABM, Sklovsky E, Sayers L, et al. Comparison of serum oestrogen concentrations in postmenopausal women taking estrone sulphate and estradiol Br Med J 1978; 1: 140–2Google Scholar
- 12.Gibaldi M, Perrier D. Pharmacokinetics (2nd ed, revised and expanded). Drugs and the pharmaceutical sciences. Vol. 15. New York: Dekker, 1982Google Scholar
- 13.Rowland M, Tozer T. Clinical pharmacokinetics-concepts and applications (2nd ed). Philadelphia: Lea & Feibiger, 1989Google Scholar
- 16.Svensson LO, Johnson SH, Olsson SE. Plasma concentration of medroxyprogesteroner acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence®/ Provera® and Divina®. A randomized, single-blind, triple cross-over bioavailability study in menopausal women. Maturitas 1994; 18: 229–38PubMedCrossRefGoogle Scholar
- 17.Englund DE, Johansson EDB. Pharmacokinetic and pharmaco-dynamic studies on estradiol valerate administered orally to postmenopausal women. Acta Obstet Gynecol Scand Suppl 1997; 65: 27–31Google Scholar
- 25.Sahlin L, von Schoultz B. Liver inclusive protein, lipid and carbohydrate metabolism. In: Oettel M, Schillinger E, editors. Handbook of experimental pharmacology 135/II: estrogens and antiestrogens II. Berlin: Springer-Verlag, 1999: 323–51Google Scholar